-
Mashup Score: 2
Eric Donnenfeld, MD, highlights study results exhibiting risuteganib as a potential treatment option for dry eye disease.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet
-
Mashup Score: 0ASCRS Annual Meeting flashback: Scott Gottlieb, MD, shares thoughts on reducing risk in the future - EyeWorld - 2 year(s) ago
Scott Gottlieb, MD, former FDA commissioner, spoke at the 2021 ASCRS Annual Meeting in July 2021 in Las Vegas, Nevada, giving an overview of the state of the COVID-19 pandemic at the time, providing insight on how the nation got to where it was at that time, and sharing his thoughts on how the country could reduce its risk in the future.
Source: EyeWorldCategories: Latest Headlines, OphthalmologyTweet-
Flashback: The ASCRS Annual Meeting is known for world-class experts, like former FDA Commissioner Scott Gottlieb, MD. Click the link to hear his thoughts on COVID-19 and reducing risk in the future - https://t.co/2tdyCauhXZ #ASCRS2021 #ASCRS2022 #COVID19 #pandemic https://t.co/rKadceBiIJ
-
-
Mashup Score: 2
Eric Donnenfeld, MD, highlights study results exhibiting risuteganib as a potential treatment option for dry eye disease.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
. @DonnenfeldEric explores risuteganib for DED: Promising treatment with increased TBUT, low staining scores: https://t.co/O0FRQZ0qN4 #Ophthalmology #DryEyeDisease #DED #ASCRS2021 https://t.co/IHgDQYsvyE
-
-
Mashup Score: 0Grail Study shows refractive stability of Juvene IOL - 2 year(s) ago
Eric Donnenfeld, MD, presents results of the year-long Grail Study demonstrating the safety and performance of the Juvene IOL from LensGen Inc.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
. @DonnenfeldEric presents results of the year-long Grail Study demonstrating the safety and performance of the Juvene #IOL from LensGen Inc. https://t.co/QkRRH0VyFN #Ophthalmology #ASCRS #Cataract #Refractive #ASCRS2021
-
-
Mashup Score: 0
Eric Donnenfeld, MD, highlights study results exhibiting risuteganib as a potential treatment option for dry eye disease.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
. @DonnenfeldEric explores risuteganib for DED: Promising treatment with increased TBUT, low staining scores: https://t.co/GjIcVoMPuB #Ophthalmology #DryEyeDisease #DED #ASCRS #ASCRS2021: https://t.co/qlGipKKHPs
-
-
Mashup Score: 3
Eric Donnenfeld, MD, highlights study results exhibiting risuteganib as a potential treatment option for dry eye disease.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
. @DonnenfeldEric explores risuteganib for DED: Promising treatment with increased TBUT, low staining scores: https://t.co/eOp8wsa0rj #Ophthalmology #DryEyeDisease #DED #ASCRS #ASCRS2021: https://t.co/hMcywFXZKJ
-
-
Mashup Score: 2Evaluating efficacy, safety of intracameral dexamethasone 9% vs topical regimen for cataract surgery - 3 year(s) ago
Robert Weinstock, MD, discusses the efficacy and safety of intracameral dexamethasone suspension 9% compared to standard of care topical regimen for eyes receiving cataract surgery.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
. @rjweinstockmd discusses the efficacy, safety of intracameral dexamethasone suspension 9% compared to standard of care topical regimen for #CataractSurgery. WATCH the full interview: https://t.co/9PhpbfcXI3 #Ophthalmology #Cataract @EyeInstituteWFL #ASCRS2021 @EyePointPharma https://t.co/80YvofWIhl
-
-
Mashup Score: 2RVL Pharmaceuticals: Shifting toward ocular aesthetics - 3 year(s) ago
COO JD Schaub provides an overview of how RVL Pharmaceuticals has shifted toward becoming an ocular aesthetics company, with the sole purpose to fully focus on UPNEEQ®.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
WATCH: JD Schaub discusses how RVL Pharmaceuticals has shifted toward becoming an ocular aesthetics company, with the sole purpose to fully focus on UPNEEQ®. See the full interview: https://t.co/MMp71rgRpk #ASCRS #ASCRS2021 #RVL #Ophthalmology #Ocular https://t.co/MSClNOsaGl
-
-
Mashup Score: 3ViaLase CEO talks innovations in glaucoma treatment - 3 year(s) ago
Tibor Juhasz, CEO of ViaLase, Inc, discusses the company’s development of a novel, noninvasive high-resolution OCT image-guided femtosecond laser technology for the treatment of open-angle glaucoma.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
WATCH: Tibor Juhasz, CEO of ViaLase, Inc, discusses the company's development of a novel, noninvasive high-resolution #OCT image-guided femtosecond laser technology for the treatment of #glaucoma. https://t.co/l56lPOcDjg #Ophthalmology #ASCRS #ASCRS2021 #ViaLase https://t.co/92TWwvZZIK
-
-
Mashup Score: 2Evaluating efficacy, safety of intracameral dexamethasone 9% vs topical regimen for cataract surgery - 3 year(s) ago
Robert Weinstock, MD, discusses the efficacy and safety of intracameral dexamethasone suspension 9% compared to standard of care topical regimen for eyes receiving cataract surgery.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
. @rjweinstockmd discusses the efficacy, safety of intracameral dexamethasone suspension 9% compared to standard of care topical regimen for #CataractSurgery. WATCH the full interview: https://t.co/GLAfXmgM7p #Ophthalmology #Cataract @EyeInstituteWFL #ASCRS2021 @EyePointPharma https://t.co/yefrID5Rn6
-
. @DonnenfeldEric explores risuteganib for DED: Promising treatment with increased TBUT, low staining scores: https://t.co/I2PbX7MCn9 #Ophthalmology #DryEyeDisease #DED #ASCRS #ASCRS2021 https://t.co/BpzqA256VS